Skip to main content
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. — Investor Relations & Filings

Ticker · EWTX ISIN · US28036F1057 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2023-06-22 Delisting Announcement
Country US United States of America
Listing US EWTX

About Edgewise Therapeutics, Inc.

https://edgewisetx.com/

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for severe and rare muscle disorders. The company leverages its expertise in muscle science to create precision medicines for conditions including muscular dystrophies and serious cardiac diseases. Its primary goal is to develop treatments that address the underlying causes of these debilitating conditions to improve the lives of patients and their families.

Recent filings

Filing Released Lang Actions
FORM 8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Edgewise Therapeutics, Inc. dated June 19, 2023. It reports the resignation of a director and the resulting non-compliance with Nasdaq listing rules regarding the audit committee composition. The document does not contain financial statements or detailed financial analysis but is an announcement of a corporate governance event and regulatory compliance issue. It specifically includes sections titled 'Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' and 'Item 5.02 Departure of Directors or Certain Officers.' This matches the description of a Delisting Announcement (DLST) because it notifies Nasdaq and investors about the company's failure to meet a listing standard and the related director resignation. Although it mentions a cure period and plans to regain compliance, it is not a full annual or interim report, nor an earnings release or management discussion. Therefore, the best classification is DLST with high confidence.
2023-06-22 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 15, 2023, by Edgewise Therapeutics, Inc. It reports the entry into a material definitive agreement (a Sales Agreement with BofA Securities for an ATM offering) and the termination of a prior Sales Agreement. The content focuses on financing activities, specifically the terms and conditions of the sales agreement for issuing common stock. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The document is not a proxy, governance, or legal proceeding report. It clearly relates to capital raising and financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7748 characters) supports it being a substantive filing rather than a brief announcement or certification.
2023-06-16 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a sales agreement for common stock offering. It includes detailed information about the terms of the offering, use of proceeds, risk factors, and plan of distribution. The document is a formal offering document for capital raising, specifically describing an 'at the market offering' of common stock. This type of filing corresponds to a Capital/Financing Update, as it provides updates on company fundraising and financing activities. It is not an annual or quarterly report, nor an earnings release or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2023-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2023-06-15 English
PRIMARY DOCUMENT
Director's Dealing
2023-06-15 English
PRIMARY DOCUMENT
Director's Dealing
2023-06-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.